Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Rani Therapeutics Holdings has reported Preferred Stock Liabilities for 2 years, with the latest figure at $191.0 million in Q2 2021.

• On a quarterly basis, Preferred Stock Liabilities rose 65.39% year-over-year to $191.0 million in Q2 2021; TTM through Jun 2021 was $191.0 million, a 65.39% increase from a year earlier, with the FY2020 full-year figure at $184.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities was $191.0 million for Q2 2021 at Rani Therapeutics Holdings, roughly flat from $191.0 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $191.0 million in Q1 2021, with the low at $115.5 million in Q2 2020.